8-K filed March 11, 2025, 7:59 PM ET ticker MTNB CIK 0001582554

leadership confidence high sentiment neutral materiality 0.60

Matinas BioPharma appoints Keith Murphy and Edward Neugeboren to board; two directors resign

Matinas BioPharma Holdings, Inc.

Natasha Giordano and Matthew Wikler resigned from the Board effective Feb 11, 2025, not due to any disagreement.
Keith Murphy (Organovo Executive Chairman) appointed director, Chair of Governance Committee, Compensation Committee member.
Edward Neugeboren (Cronus Pharma Chief Strategy Officer) appointed director, Chair of Compensation, Audit Committee member.
Neugeboren qualifies as audit committee financial expert; both are independent under NYSE and SEC rules.
New directors bring significant healthcare, biotech, and capital markets experience; effective March 11, 2025.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Edward Neugeboren

Director

MTNB · Matinas BioPharma Holdings, Inc.

Effective: 2025-03-11
Filed: March 11, 2025, 7:59 PM ET

The Board appointed Mr. Neugeboren to serve as a member of the Audit Committee and as Chair of the Compensation Committee.

Departed

Natasha Giordano

Director

MTNB · Matinas BioPharma Holdings, Inc.

Effective: 2025-02-11
Successor: Keith Murphy
Filed: March 11, 2025, 7:59 PM ET

On February 10, 2025, Natasha Giordano informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that she was resigning from the Board effective February 11, 2025, due to her other professional obligations.

Departed

Matthew Wikler

Director

MTNB · Matinas BioPharma Holdings, Inc.

Effective: 2025-02-11
Successor: Edward Neugeboren
Filed: March 11, 2025, 7:59 PM ET

On February 10, 2025, Matthew Wikler informed the Board that he was resigning from the Board effective February 11, 2025, due to his other professional obligations.

Appointed

Keith Murphy

Director

MTNB · Matinas BioPharma Holdings, Inc.

Effective: 2025-03-11
Filed: March 11, 2025, 7:59 PM ET

Effective as of March 11, 2025, the Board, on the recommendation of the Governance Committee, appointed Keith Murphy and Edward Neugeboren directors of the Company to replace Ms. Giordano and Mr. Wikler, respectively.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Edward Neugeboren was appointed as Director at Matinas BioPharma Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

The Board appointed Mr. Neugeboren to serve as a member of the Audit Committee and as Chair of the Compensation Committee.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Natasha Giordano resigned as Director at Matinas BioPharma Holdings, Inc..

Action: resigned
Role: Director

Exact text from the filing

On February 10, 2025, Natasha Giordano informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that she was resigning from the Board effective February 11, 2025, due to her other professional obligations.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Wikler resigned as Director at Matinas BioPharma Holdings, Inc..

Action: resigned
Role: Director

Exact text from the filing

On February 10, 2025, Matthew Wikler informed the Board that he was resigning from the Board effective February 11, 2025, due to his other professional obligations.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Keith Murphy was appointed as Director at Matinas BioPharma Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective as of March 11, 2025, the Board, on the recommendation of the Governance Committee, appointed Keith Murphy and Edward Neugeboren directors of the Company to replace Ms. Giordano and Mr. Wikler, respectively.

View on SEC.gov

Matinas BioPharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-009775

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.